Pharmaceutical Giants Avoid Peptide Market Amid Rising Interest

Interest in illegal peptides is rising, yet major pharmaceutical companies are not pursuing legitimate production. Despite the growing demand, these companies remain hesitant to invest in the peptide market, citing regulatory challenges and potential risks. This trend raises questions about the future of peptide-based therapies.

Read the full story at Sydney Morning Herald→